These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23767437)

  • 1. There may be costs to failing to enhance, as well as to enhancing.
    Levy N
    Am J Bioeth; 2013; 13(7):38-9. PubMed ID: 23767437
    [No Abstract]   [Full Text] [Related]  

  • 2. Regulating methylphenidate: enhancing cognition and social inequality.
    Brewer CD; DeGrote H
    Am J Bioeth; 2013; 13(7):47-9. PubMed ID: 23767442
    [No Abstract]   [Full Text] [Related]  

  • 3. The indirect psychological costs of cognitive enhancement.
    Faulmüller N; Maslen H; de Sio FS
    Am J Bioeth; 2013; 13(7):45-7. PubMed ID: 23767441
    [No Abstract]   [Full Text] [Related]  

  • 4. Moving beyond methylphenidate and amphetamine: the ethics of a better "smart drug".
    LaBuzetta JN
    Am J Bioeth; 2013; 13(7):43-5. PubMed ID: 23767440
    [No Abstract]   [Full Text] [Related]  

  • 5. Constraints on regulatory options for putatively cognitive enhancing drugs.
    Hall W; Partridge B; Lucke J
    Am J Bioeth; 2013; 13(7):35-7. PubMed ID: 23767436
    [No Abstract]   [Full Text] [Related]  

  • 6. Some first steps toward responsible use of cognitive-enhancing drugs by the healthy.
    Greely HT
    Am J Bioeth; 2013; 13(7):39-41. PubMed ID: 23767438
    [No Abstract]   [Full Text] [Related]  

  • 7. An argument for permitting amphetamines and instant-release methylphenidate.
    Flanigan J
    Am J Bioeth; 2013; 13(7):49-51. PubMed ID: 23767443
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancement policy and the value of information.
    Sandberg A
    Am J Bioeth; 2013; 13(7):34-5. PubMed ID: 23767435
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to open peer commentaries on "prohibition or coffee shops: regulation of amphetamine and methylphenidate for enhancement use by healthy adults".
    Dubljević V
    Am J Bioeth; 2014; 14(1):W1-8. PubMed ID: 24422938
    [No Abstract]   [Full Text] [Related]  

  • 10. How research on stakeholder perspectives can inform policy on cognitive enhancement.
    Forlini C; Racine E; Vollmann J; Schildmann J
    Am J Bioeth; 2013; 13(7):41-3. PubMed ID: 23767439
    [No Abstract]   [Full Text] [Related]  

  • 11. A liberal consequentialist approach to regulation of cognitive enhancers.
    Savulescu J
    Am J Bioeth; 2013; 13(7):53-5. PubMed ID: 23767445
    [No Abstract]   [Full Text] [Related]  

  • 12. Tobacco: prohibition, coffee shops, or discouragement?
    van der Eijk Y
    Am J Bioeth; 2013; 13(7):51-3. PubMed ID: 23767444
    [No Abstract]   [Full Text] [Related]  

  • 13. Prohibition or coffee shops: regulation of amphetamine and methylphenidate for enhancement use by healthy adults.
    Dubljević V
    Am J Bioeth; 2013; 13(7):23-33. PubMed ID: 23767434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Governments needs to explore alternative to prohibitionist drug policies, says report.
    Sweet M
    BMJ; 2012 Apr; 344():e2610. PubMed ID: 22492117
    [No Abstract]   [Full Text] [Related]  

  • 15. Children and drug law reform.
    Cardoso FH
    Int J Drug Policy; 2012 Jan; 23(1):1-2. PubMed ID: 22071021
    [No Abstract]   [Full Text] [Related]  

  • 16. Who is using the drugs I prescribe?
    Winkelaar PG
    Can Fam Physician; 2002 May; 48():883. PubMed ID: 12053632
    [No Abstract]   [Full Text] [Related]  

  • 17. Inconsistencies in the assumptions linking punitive sanctions and use of cannabis and new psychoactive substances in Europe.
    Hughes B; Matias J; Griffiths P
    Addiction; 2018 Dec; 113(12):2155-2157. PubMed ID: 29953686
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessing abuse liability during drug development: changing standards and expectations.
    Schoedel KA; Sellers EM
    Clin Pharmacol Ther; 2008 Apr; 83(4):622-6. PubMed ID: 18212799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gammahydroxybutyrate must remain available for patients with narcolepsy].
    Lammers GJ; van Dijk JG; Ferrari MD; van Gerven JM; Declerck AC; Troost J
    Ned Tijdschr Geneeskd; 1999 Oct; 143(41):2062-3. PubMed ID: 10560549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of the abuse potential of modafinil using methylphenidate as a reference.
    Jasinski DR
    J Psychopharmacol; 2000 Mar; 14(1):53-60. PubMed ID: 10757254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.